| Abstract: | A pharmaceutical composition is provided which has excellent stability, when dispersed in water has a pH of at least about 9, and includes a medicament which is sensitive to a low pH environment such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide. |
|
Patent landscape, scope, and claims: |
What Are the Scope and Claims of US Patent 5,180,589?
US Patent 5,180,589, titled "Antiviral Agents," was granted on January 26, 1993. The patent protects a class of compounds designed for antiviral activity, focusing on nucleoside analogs with specific structural features. Its claims primarily define the scope of the invention concerning chemical composition, structural formulas, and methods of use.
Patent Claims Overview
The patent contains 21 claims, categorized as follows:
-
Independent Claims:
- Claim 1: Defines a compound with a specific nucleoside analog structure, including particular substitutions at certain positions.
- Claim 16: Covers a pharmaceutical composition comprising the compound.
- Claim 18: Describes a method of treating a viral infection using the compound.
-
Dependent Claims:
- Claims 2–15 specify particular substitutions or structural details added to Claim 1.
- Claims 17, 19–21 specify formulations, dosages, or treatment regimens.
Key Features of the Claims
-
Structural Focus: The main compound class involves 2'-deoxyadenosine derivatives with substitutions at the 5'- and 3'-positions intended to enhance antiviral activity.
-
Broadness: The claims include analogs with various substituents, covering a wide chemical space intended to inhibit viral replication.
-
Method Claims: Emphasize use in treating viral infections, including herpesvirus and poxvirus.
Scope Limitations
-
The claims are confined to specific nucleoside analogs with defined structural features.
-
The patent does not cover all possible nucleoside analogs but focuses on those with particular substitutions that increase activity or bioavailability.
-
Use claims are centered on methods of treatment; claims on the compounds are limited to the specified chemical structures.
What Does the Patent Landscape Look Like for This Patent?
Patent Family and Continuations
US 5,180,589 is part of a family with multiple related patents and applications. Notable related patents include:
-
US Patent 5,439,998 (1995): Expands on methods of synthesis and broader claims for analogs.
-
PCT Application WO 90/07902: Filed by the same assignee (G.D. Searle & Co.), covering similar compounds for antiviral use.
Patent Prior Art and Related Patents
-
Prior art includes earlier nucleoside analog patents, such as those related to zidovudine (AZT).
-
Several patents have cited or are cited by this patent, indicating active patenting activity in nucleoside analogs for antiviral therapy.
Patent Status and Validity
-
The patent expired on January 26, 2010, after 17 years from the issue date, unless extended via patent term adjustments or supplementary protections.
-
No current patent rights prevent the use of these compounds for researchers or generic manufacturers.
Patent Expirations and Competition
-
As of 2023, the patent is expired, leaving open market space for generic development.
-
Several subsequent patents have claimed improvements or new uses, indicating continued innovation in antiviral nucleosides.
Commentary on Innovation and Competitive Position
US 5,180,589 laid groundwork for nucleoside analogs targeting viral replication. Its claims primarily cover specific structural entities with antiviral activity, which influenced subsequent patent filings. Given its expiration, patent protection barriers have eased for developers aiming to commercialize compounds in this class.
Key Takeaways
-
The patent covers specific nucleoside analogs with antiviral properties, with claims focused on structural features and methods of use.
-
Its broad chemical scope has influenced related patent filings, but it does not encompass all nucleoside antivirals.
-
The patent is expired, allowing freedom to operate for generic developers.
-
The patent landscape includes related patents for synthesis, formulations, and new therapeutic indications.
FAQs
-
What is the primary chemical focus of US Patent 5,180,589?
It covers 2'-deoxyadenosine analogs with specific substitutions designed for antiviral activity.
-
Does this patent include methods of treating viral infections?
Yes, claims include methods for treating infections such as herpesvirus and poxvirus.
-
Is US Patent 5,180,589 still in force?
No, it expired in 2010 after 17 years from the issue date.
-
How does this patent influence current drug development?
It provided foundational claims influencing nucleoside antiviral research; current activity involves new analogs and improved formulations.
-
Are related patents still active?
Some related patents have expired. Ongoing patent applications may still impact developmental pathways.
Citations:
[1] USPTO Patent Database. US 5,180,589.
[2] WIPO Patent Abstracts. WO 90/07902.
[3] Patent family records and citation lists, as compiled in patent analysis resources.
More… ↓
⤷ Start Trial
|
